Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant. Issue 1 (28th October 2021)

• Record Type: Journal Article
• Authors: Hillier, Kirsty; Harris, Emily M.; Berbert, Laura; Pai, Sung‐Yun; Grace, Rachael F.
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-10-28
• Subjects: bortezomib -- hemolytic anemia -- immune cytopenias -- rituximab -- transfusion -- transplantation; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29410
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Autoimmune hemolytic anemia (AIHA) after allogeneic hematopoietic stem cell transplant (HSCT) is a rare but complex and serious complication. Detailed descriptions of cases and management strategies are needed due to lack of prospective trials. Objectives: Describe the incidence, clinical characteristics, and management of AIHA after HSCT in a pediatric cohort. Methods: This is a retrospective cohort study of 33 pediatric patients with AIHA after HSCT at an academic tertiary care center from 2003 to 2019. Results: The overall incidence of AIHA after allogeneic HSCT was 3.8% (33/868). AIHA was significantly more common after transplant for nonmalignant versus malignant diagnoses (7.0% [26/370] vs. 1.4% [7/498], p < .0001). AIHA developed at a median of 4.7 months (range 1.0–29.7) after transplant. Sixteen of 33 patients (48.5%) required new AIHA‐directed pharmacologic therapy; 17 (51.5%) were managed on their current immunosuppression and supportive care. Patients managed without additional therapy were significantly older, more likely to have a malignant diagnosis, and tended to develop AIHA at an earlier time point after transplant. Patients received a median of two red blood cell transfusions within the first 2 weeks of diagnosis and a median of one AIHA‐directed medication (range one to four), most commonly corticosteroids and rituximab. Conclusions: AIHA after HSCT is rare but occurs more commonly in patients transplanted for nonmalignant diagnoses. While some pediatric patients who develop AIHA after transplant can be managed on current immunosuppression and supportive care, many require AIHA‐directed therapy including second‐line medications.